最新消息

Entry into Material Definitive Agreement with G Medical


Entry into Material Definitive Agreement with G Medical


Nov 16, 2017
OTC Disclosure & News Service

Wanchai, HGK, China -

Union Bridge Holdings Limited (OTCQB:UGHL) announced that they have entered into two binding Memoranda of Understanding ("MOU") with G Medical Innovations Asia Limited, a company organized under the laws of the Hong Kong and a subsidiary of G Medical Innovations Holdings Limited (http://gmedinnovations.com) listed on ASX to distribute their smart-phone based "Telemedic" device called PRIZMA in India and Taiwan.

Joseph Ho, the CEO of UGHL describes these MOUs as a landmark development for UGHL. "PRIZMA and other products from G Medical are revolutionary gadgets that put a doctor in the pocket of every consumer," said Mr. Ho. Mr. Ho further said that UGHL is determined to enter into the health care related business and is exploring a number of opportunities in the health care sphere.
 

PRIZMA

PRIZMA is a small "Telemedic" device that neatly encases a regular smart-phone making it a constant companion of the user. With PRIZMA consumers are able to record their vital medical parameters such as ECG, heart rate and rhythm, oxygen saturation levels in the body, body temperature and overall stress levels by simply holding the device correctly. The recorded data are then transmitted over the internet to a special G Medical call center, where they are interpreted by G Medical, and consumers are alerted if any abnormality is observed.

PRIZMA is a result of years of technological innovation by a group of dedicated engineers and programmers. The next generation of PRIZMA is currently set to be introduced in 2018/9 which will have more tests, including tests for blood sugar and cholesterol.

The Prizma device has US Food and Drug Administration clearance and European Union CE Mark approval.


Forward Looking Statements

This Press Release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements concerning plans, objectives, goals, strategies, expectations, future events or performance and underlying assumptions and other statements which are other than statements of historical facts. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "plan," "project," "anticipate," "estimate," "believe," or " think." Forward-looking statements involve risks and uncertainties which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Investors should carefully review the risk factor disclosure and other information, including the Companys financial statements and the notes thereto, set forth in the reports and other documents the Company files with the SEC available at www.sec.gov.

We assume no duty to update or revise our forward-looking statements based on changes in plans or expectations or otherwise.

This release includes additional documents. Select the link(s) below to view.
UGHL Press Release re PRIZMA (00186148-2xA7D54) final clean.pdf
Copyright © 2017 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

網址連結>>> http://www.otcmarkets.com/stock/UGHL/news/Entry-into-Material-Definitive-Agreement-with-G-Medical?id=175542&b=y